Literature DB >> 3804903

Treatment of skin and soft tissue infections with oral ciprofloxacin.

R J Fass.   

Abstract

Thirty adult patients with severe skin and soft tissue infections (four with contiguous osteomyelitis) caused by a variety of bacterial pathogens were treated with oral ciprofloxacin. Favourable clinical responses were observed in 23 (92%) of the 25 evaluable cases. All Enterobacteriaceae and anaerobic bacteria were eradicated during treatment. Enterococci, Staphylococcus aureus, and Pseudomonas aeruginosa were usually eradicated but occasional strains persisted during treatment. Strains that persisted during treatment were associated with therapeutic failure in two cases, one with contiguous osteomyelitis and one with vascular gangrene. The only significant adverse reaction observed was nausea and/or vomiting in five of the 30 patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3804903     DOI: 10.1093/jac/18.supplement_d.153

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients.

Authors:  M Müller; M Brunner; U Hollenstein; C Joukhadar; R Schmid; E Minar; H Ehringer; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Distribution and antimicrobial activity of ciprofloxacin in human soft tissues.

Authors:  M Brunner; U Hollenstein; S Delacher; D Jäger; R Schmid; E Lackner; A Georgopoulos; H G Eichler; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Target site concentrations of ciprofloxacin after single intravenous and oral doses.

Authors:  Martin Brunner; Heino Stabeta; Jan-Georg Möller; Claudia Schrolnberger; Boban Erovic; Ursula Hollenstein; Markus Zeitlinger; Hans Georg Eichler; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 4.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

Review 5.  Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.

Authors:  H van Poppel; V Chyský; R Hullmann; L Baert
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 6.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.

Authors:  A E Simor; S A Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 8.  Bacterial resistance to fluoroquinolones: lessons to be learned.

Authors:  P Ball
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 9.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.